0001493152-21-031964.txt : 20211220 0001493152-21-031964.hdr.sgml : 20211220 20211220060613 ACCESSION NUMBER: 0001493152-21-031964 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211217 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211220 DATE AS OF CHANGE: 20211220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lineage Cell Therapeutics, Inc. CENTRAL INDEX KEY: 0000876343 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943127919 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12830 FILM NUMBER: 211503580 BUSINESS ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 5105213390 MAIL ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 FORMER COMPANY: FORMER CONFORMED NAME: BIOTIME INC DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm
0000876343 false 0000876343 2021-12-17 2021-12-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 17, 2021

 

Lineage Cell Therapeutics, Inc.

(Exact name of registrant as specified in charter)

 

California   001-12830   94-3127919

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

2173 Salk Avenue, Suite 200

Carlsbad, California

   92008
(Address of principal executive offices)   (Zip Code)

 

(442) 287-8990

Registrant’s telephone number, including area code

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common shares, no par value   LCTX   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On December 17, 2021, Lineage Cell Therapeutics, Inc. and its subsidiary, Cell Cure Neurosciences Ltd. (“Cell Cure” and collectively, “Lineage”) entered into a Collaboration and License Agreement (the “Agreement”) with F. Hoffmann-La Roche Ltd and Genentech, Inc., a member of the Roche Group (collectively, “Roche”), wherein Lineage granted to Roche exclusive worldwide rights to develop and commercialize retinal pigment epithelium (“RPE cells”) cell therapies, including its proprietary cell therapy known as OpRegen®, for the treatment of ocular disorders, including advanced dry age-related macular degeneration with geographic atrophy.

 

Under the terms of the Agreement, Roche will assume responsibility for further clinical development and commercialization of OpRegen®, which currently is being evaluated in a Phase 1/2a open-label, dose escalation clinical safety and efficacy study in patients with advanced dry age-related macular degeneration with geographic atrophy. Lineage will be responsible for completing activities related to the ongoing clinical study, for which enrollment is complete, and performing certain manufacturing and process development activities.

 

Roche will pay Lineage a $50 million upfront payment and Lineage is eligible to receive up to an additional $620 million in certain developmental, regulatory and commercialization milestone payments. Lineage is also eligible for tiered double-digit percentage royalties on net sales of OpRegen. All regulatory and commercial milestone payments, and royalty payments, are subject to the existence of certain intellectual property rights that cover OpRegen at the time such payments would otherwise become due, and the royalties on net sales of OpRegen are subject to financial offsets based on the existence of competing products.

 

The OpRegen program has been supported in part with contributions made by Hadasit Medical Research Services and Development Ltd. (“Hadasit”), the technology transfer company of Hadassah Medical Center, and the Israeli Innovation Authority (the “IIA”), an independent agency created to address the needs of global innovation ecosystems. A significant portion of early development on the OpRegen program occurred at Cell Cure, which is a 99%-owned subsidiary of Lineage. Cell Cure was established by the Hadassah Medical Center, where the intellectual property underlying the differentiation and manufacture of RPE cells originated. In addition, significant monetary support for the OpRegen program was provided by the IIA through a series of separate research grants, beginning in 2007. Each of these parties’ contributions began when the OpRegen program was in its earliest stages of development. As a result, and subject to the terms of contracts among the applicable parties, Lineage is obligated to pay Hadasit and the IIA a portion of the upfront, milestone, and royalty payments which may be received from Roche under the Agreement. Lineage is obligated to pay approximately 24.3% of the upfront payment and any milestone payments, and 3% of all royalty payments it receives from Roche to the IIA, up to an aggregate cap on all payments to IIA of approximately $103 million.

 

In addition, pursuant to that certain Second Amended and Restated License Agreement, dated June 15, 2017, between Cell Cure and Hadasit, as amended, and a certain letter agreement entered into on December 17, 2021, by and between Cell Cure and Hadasit, Cell Cure is obligated to pay to Hadasit a maximum of 21.5% of the upfront payment (subject to certain reductions) and any milestone payments, and up to 50% of all royalty payments (subject to a maximum payment of 5% of net sales of products), Lineage receives from Roche. The letter agreement generally terminates upon the termination of the Agreement.

 

Unless earlier terminated by either party, the Agreement will expire on a product-by-product and country-by-country basis upon the expiration of all of Roche’s payment obligations under the Agreement. Roche may terminate the Agreement in its entirety, or on a product-by-product or country-by-country basis, at any time with advance written notice. Either party may terminate the Agreement in its entirety with written notice for the other party’s material breach if such party fails to cure the breach. Either party also may terminate the Agreement in its entirety upon certain insolvency events involving the other party.

 

The representations, warranties and covenants contained in the Agreement were made only for the purposes of the Agreement, were made as of specific dates, were made solely for the benefit of the parties to the Agreement and may not have been intended to be statements of fact, but rather, as a method of allocating risk and governing the rights and relationships among the parties to the Agreement. In addition, such representations, warranties and covenants may have been qualified by certain disclosures not reflected in the text of the Agreement and may apply standards of materiality and other qualifications and limitations in a way that is different from what may be viewed as material by Lineage’s shareholders. In reviewing the representations, warranties and covenants contained in the Agreement, it is important to bear in mind that such representations, warranties and covenants were not intended by the parties to the Agreement to be characterizations of the actual state of facts or conditions of Lineage or OpRegen®. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Agreement, which subsequent information may or may not be fully reflected in public disclosures. For the foregoing reasons, the representations, warranties and covenants in the Agreement should not be read alone and should instead be read in conjunction with the other information contained in the reports, statements and filings that Lineage publicly files with the U.S. Securities and Exchange Commission.

 

 
 

 

Item 7.01. Regulation FD Disclosure.

 

On December 20, 2021, Lineage issued a press release announcing its entry into the Agreement. A copy of the press release is attached as Exhibit 99.1 to this report.

 

The information contained in this Item 7.01, including in Exhibit 99.1 to this report, is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 or 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in Exhibit 99.1 shall not be incorporated by reference into any filing with the Securities and Exchange Commission (“SEC”) made by Lineage, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Cautionary Statement Regarding Forward-Looking Statements

 

Lineage cautions you that all statements, other than statements of historical facts, contained in this report, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “suggest,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the further clinical development and commercialization of OpRegen®, Lineage’s ability to complete its obligations under the Agreement, the potential future achievement of specified developmental, regulatory and commercialization milestones, and the potential future receipt of payments therefrom. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the SEC. Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

  

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press release dated December 20, 2021.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Lineage Cell Therapeutics, Inc.
     
Date: December 20, 2021 By: /s/ George A. Samuel III
  Name:  George A. Samuel III
  Title: General Counsel and Corporate Secretary

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

LINEAGE ESTABLISHES EXCLUSIVE WORLDWIDE COLLABORATION WITH

GENENTECH FOR THE DEVELOPMENT AND COMMERCIALIZATION OF OPREGEN®

RPE CELL THERAPY FOR THE TREATMENT OF OCULAR DISORDERS

 

  ●Genentech Will Pay Lineage $50 Million Upfront
  ●Eligible to Receive a Total of $670 Million in Upfront and Milestone Payments
  ●Conference Call to Discuss Collaboration Planned for 8 a.m. ET

 

CARLSBAD, CA– December 20, 2021 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), today announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and license agreement with Roche and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the development and commercialization of a retinal pigment epithelium (RPE) cell therapy for the treatment of ocular disorders, including advanced dry age-related macular degeneration (dry AMD) with geographic atrophy (GA).

 

Genentech will assume responsibility for further clinical development and commercialization of Lineage’s OpRegen program, which currently is being evaluated in a Phase 1/2a open-label, dose escalation clinical safety and efficacy study in patients with advanced dry AMD with GA. Under the terms of the collaboration agreement, Lineage will complete activities related to the ongoing clinical study, for which enrollment is complete, and perform certain manufacturing activities. Genentech will pay Lineage a $50 million upfront payment and Lineage is eligible to receive up to $620 million in additional development, approval and sales milestone payments, in addition to tiered double- digit royalties.

 

“Genentech is a clear global leader in ophthalmology and has demonstrated a longstanding commitment to patients, innovative research and successful product development,” said Brian M. Culley, Lineage’s CEO. “Their desire to combine our cell therapy technology with their ophthalmology expertise and capabilities will help advance the OpRegen program more rapidly and we believe successfully to patients with serious ocular disorders, such as dry age-related macular degeneration. Lineage’s objective is to pioneer a new branch of regenerative medicine, based on transplanting whole cells into the body to restore activity lost to aging, injury or disease. We believe the results we have demonstrated to date with OpRegen represent a paradigm change many did not believe possible with cell therapy, by restoring retinal tissue and potentially halting or reversing the expansion of geographic atrophy. I am incredibly proud of what the Lineage team has accomplished with the OpRegen program and look forward to joining forces with the Genentech team as they work to take this program to the next level and potentially to patients in need of treatment.”

 

Mr. Culley continued, “Looking ahead, Lineage will remain focused on advancing our spinal cord injury and oncology programs as well as announcing new disease settings where we plan to deploy our technology, either on our own or through strategic alliances. All of us at Lineage are immensely proud to have the opportunity and responsibility to advance a new and exciting branch of medicine, and our aim is to make a profound impact on the patients who serve as our inspiration.”

 

“Genentech has a longstanding commitment to discovering and developing novel drugs for the treatment of serious eye disorders such as with advanced dry AMD with GA, which is one of our focus areas within ophthalmology,” said James Sabry, M.D., Ph.D., global head of Pharma Partnering, Roche. “We are excited to partner with Lineage Cell Therapeutics to advance potential new therapies in an area of high unmet medical need.”

 

Conference Call Information

 

Lineage will host a live conference call and webcast today beginning at 8 a.m. ET to discuss the collaboration with the Roche Group and Genentech. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through December 27, 2021, by dialing (855) 859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere outside the U.S. and Canada and entering conference ID number 5174206.

 

 
 

 

About OpRegen

 

OpRegen has been developed in part through contributions and financial grants made by Hadasit Medical Research Services and Development Ltd. (“Hadasit”) and the Israeli Innovation Authority (the “IIA”). Lineage is obligated to pay a portion of upfront, milestone and royalty payments it receives to Hadasit and the IIA. OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with a best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA). Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. The primary objective of the study was to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. OpRegen has been well tolerated to date and there have been no new, unexpected ocular or systemic adverse events or serious adverse events related to OpRegen or study procedures that have not been previously reported.

 

About Lineage Cell Therapeutics, Inc.

 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

 

Forward-Looking Statements

 

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “aim,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the collaboration and license agreement with Roche and Genentech and activities expected to occur under the collaboration and license agreement, the upfront, milestone and royalty consideration payable to Lineage, the potential benefits of treatment with OpRegen, and Lineage’s plans to advance its spinal cord injury and oncology programs and announce new disease settings where it plans to deploy its technology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including the risk that competing alternative therapies may adversely impact the commercial potential of OpRegen, which could materially adversely affect the milestone and royalty payments payable to Lineage under the collaboration and license agreement, the risk that Roche and Genentech may not be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction, and risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

Page 2
 

 

Lineage Cell Therapeutics, Inc. IR

Ioana C. Hone

(ir@lineagecell.com)

(442) 287-8963

 

Solebury Trout IR

Mike Biega

(Mbiega@soleburytrout.com)

(617) 221-9660

 

Russo Partners – Media Relations

Nic Johnson or David Schull

Nic.johnson@russopartnersllc.com

David.schull@russopartnersllc.com

(212) 845-4242

 

###

 

Page 3

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 lctx-20211217.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 lctx-20211217_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 lctx-20211217_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Dec. 17, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 17, 2021
Entity File Number 001-12830
Entity Registrant Name Lineage Cell Therapeutics, Inc.
Entity Central Index Key 0000876343
Entity Tax Identification Number 94-3127919
Entity Incorporation, State or Country Code CA
Entity Address, Address Line One 2173 Salk Avenue
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92008
City Area Code (442)
Local Phone Number 287-8990
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares, no par value
Trading Symbol LCTX
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000876343 2021-12-17 2021-12-17 iso4217:USD shares iso4217:USD shares 0000876343 false 8-K 2021-12-17 Lineage Cell Therapeutics, Inc. CA 001-12830 94-3127919 2173 Salk Avenue Suite 200 Carlsbad CA 92008 (442) 287-8990 false false false false Common shares, no par value LCTX NYSEAMER false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://lineagecell.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm lctx-20211217.xsd lctx-20211217_lab.xml lctx-20211217_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "lctx-20211217_lab.xml" ] }, "presentationLink": { "local": [ "lctx-20211217_pre.xml" ] }, "schema": { "local": [ "lctx-20211217.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "LCTX", "nsuri": "http://lineagecell.com/20211217", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-12-17to2021-12-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://lineagecell.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-12-17to2021-12-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://lineagecell.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001493152-21-031964-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-031964-xbrl.zip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end